Dual GIP/GLP-1 Receptor Agonist
Mounjaro®(Tirzepatide)
Dual-Action Weight Loss with Blood Sugar Control
Mounjaro® (tirzepatide) is a revolutionary dual-action medication that targets both GIP and GLP-1 receptors for powerful weight loss and blood sugar management.
Avg weight loss
20-22%
vs retail
75%
up to 75% savings vs ~$1100/mo retail
Frequency
Once Weekly
Most patients start at $275/mo. Some starting options are as low as $149/mo. Final pricing is set with your provider during your consultation.
How Mounjaro works
Tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual mechanism enhances insulin secretion, reduces glucagon, slows gastric emptying, and significantly decreases appetite. The combined effect creates a powerful metabolic shift that helps patients lose substantially more weight than single-receptor medications.
Clinical evidence: In the SURMOUNT-1 trial, patients taking the highest dose of tirzepatide lost an average of 22.5% of their body weight over 72 weeks.
Benefits at PWL
- Industry-leading 20-22% average body weight loss
- Dual GIP/GLP-1 mechanism for enhanced results
- Once-weekly self-administered injection
- Significantly reduces appetite and cravings
- Excellent blood sugar control for diabetics
- May improve cardiovascular risk factors
- Helps preserve lean muscle mass
- Reduces inflammation markers
Common side effects
- Nausea (usually temporary, improves after 2-4 weeks)
- Diarrhea or constipation
- Decreased appetite (expected therapeutic effect)
- Injection site reactions (mild redness)
- Acid reflux or indigestion
Side effects are typically mild and improve over time. Your provider will guide you on managing any symptoms during your monthly check-ins.